Erin E. Jones
Vice President, Global Regulatory Affairs, Medical Writing, and Pharmacology/Toxicology
Mr. Jones joined Puma as our Vice President, Global Regulatory Affairs in 2014. Prior to joining Puma, Mr. Jones worked at BioMarin Pharmaceutical Inc. between 2012 and 2014, with Regulatory oversight of the PKU, gene therapy, and oncology programs.
While working at Genentech from 2006 to 2012, he held a variety of positions including North America Oncology Team Leader, HER Franchise Group Leader, and Head of Regulatory Intelligence. In his roles at Genentech, Mr. Jones oversaw the HER mechanism franchise, where he led and oversaw Regulatory aspects of late-stage development and BLA submissions for Kadcyla™ and Perjeta™ in HER2-positive metastatic breast cancer, and obtained approvals for Herceptin™ in HER2-positive adjuvant breast and metastatic gastric cancers.
Previously, he worked at Cephalon Inc. on strategies that led to the approval for Treanda™ in NHL and CLL, and at Centocor Inc. in increasing levels of responsibility in the areas of Discovery Research, Clinical Pharmacology, Clinical, and Regulatory.
Mr. Jones received a B.S. from the University of Pittsburgh in 1994, and an M.S. from Pennsylvania State University in 2001.
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024